KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.98

Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.

Yinbiao Zhu, Mengxue Si, Lei Wang, Yunyun Zhang, Tianxin Zhu, Jianhua Wu, Yun Zhang, Qi Shuai, Wei Lu, Wenlin Ma, Mengyuan Zhao, Shihui Zhu, Yang Tang, Jun Yu

Vaccine 68 127962

PMID41207071
PMCID-
DOI10.1016/j.vaccine.2025.127962
发表日期2025-11-09
入排依据:未发现恶性肿瘤人群证据。
入排复审未纳入:未发现恶性肿瘤人群证据。
摘要

摘要

This study aims to evaluate the tolerability, safety, and preliminary immunogenicity of quadrivalent influenza virus split vaccine (IIV4) in healthy infants and young children aged 6-35 months across different dosages. Employing a single-center, dose-escalation, open-label Phase I clinical trial design, 60 participants were randomly divided into a low-dose group (0.25 mL per dose) and a high-dose group (0.5 mL per dose). Participants received two intramuscular doses administered 28 days apart. Safety results: The overall adverse reaction rates were 23.3 % in the low-dose group and 20.0 % in the high-dose group, with no statistical difference (P > 0.05). One case of grade 3 local adverse reaction (erythema at the injection site) occurred in the high-dose group, and the remaining were mild reactions of grade 1-2. No severe adverse events were related to the vaccine. Immunogenicity results: Total population: After two doses, the GMT and GMI against H3N2 and B/Yamagata influenza strains in the high-dose group suggested a potential superiority over the low-dose group (P < 0.05). Pre-vaccination susceptible population: The high-dose group exhibited a more significant increase in GMT against H3N2 (31.7 vs. 13.2, P = 0.0482). Additionally, both groups showed significantly higher seroconversion rates, GMT, and GMI after two doses compared to one dose (P < 0.05), confirming that the two-dose schedule effectively enhances immune responses. Notably, the high-dose group demonstrated a more pronounced trend of response enhancement. Conclusion: Both the low-dose group and high-dose group IIV4 demonstrated good tolerability and safety in infants and young children aged 6-35 months. The high-dose group showed a potential advantage in immune responses to certain antigens. However, due to limitations such as the small sample size and exclusion of high-risk populations, further multi-center, large-sample Phase III clinical trials are needed to validate the clinical significance of the dose effect and provide evidence for influenza prevention and control strategies in young children. Trial registration: CXSL1800038.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。